Genenta Raised other $8,4 Million (€7 Million) in the Second Round of Financing – Total Raised in Two Rounds, $20,4 Million (€17 Million)
Guido Guidi, M.D. joined the Board of Directors, prof. Kenneth C. Anderson, M.D. joined the Scientific Advisory Board, and a new office at Alexandria LaunchLabs®, NYC has been opened.
Milano (Italy), Sept. 13, 2017. Genenta Science, a biotech company committed to the development and commercialization of a hematopoietic stem cell gene therapy for tumors treatment, today announced the closing of a
$8 Million (€7 Million) Series B financing. The Round was led by Italian, British, and Swiss private investors, family offices, and business angels, Series A investors and Board Members. The offering was oversubscribed.
Genenta banked a Series A financing in March 2015. The total amount raised in two Rounds is equal to $20,4 Million (€17 Million).
Guido Guidi, M.D. was appointed as a Board Member. Dr. Guidi served as Head of Pharma Region Europe and previously as Head of Oncology Europe at Novartis where he developed and launched several blockbuster products: Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge, Zometa, Femara e Glivec. He was also a member of the Novartis Pharma Executive Committee (PEC) and Chairman of the Novartis European Executive Committee (EEC).
Prof. Kenneth C. Anderson is now part of the Scientific Advisory Board led by prof. Luigi Naldini, Genenta’s co-founder. Prof. Anderson directs the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana- Faber Cancer Institute. And he is the Kraft Family Professor of Medicine at Harvard Medical School and the President Elect of ASH – American Society of Hematology.
Genenta landed at Alexandria LaunchLabs®, the New York City’s premier startup platform located at the Alexandria Center® for Life Science, with the aim to explore the US market.
“People matter more than anything else in this business: Carlo Russo, M.D. joined Genenta as CMO last January and now Guido and prof. Anderson are part of the Company. We focused on great people to develop the Luigi Naldini’s science and our corporate culture.” said Pierluigi Paracchi, Chairman and Chief Executive Officer. “Advancing our transformative gene therapy for patients is incredibly motivating. And with this new Round, we’ve banked enough cash to open a second tumor indication in addition to multiple myeloma”.